| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701115 | European Journal of Surgical Oncology (EJSO) | 2016 | 6 Pages |
Abstract
RSSH plus or less pelvic lymphadenectomy is technically feasible, safe and reproducible and could be the treatment of choice for patients affected by FIGO stage I-II endometrial cancer. However, randomized controlled trials are needed to confirm these results.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
G. Corrado, L. Mereu, S. Bogliolo, V. Cela, L. Freschi, R. Carlin, B. Gardella, E. Mancini, S. Tateo, A. Spinillo, E. Vizza,